Kurum Yazarı "Demir, Hacer" PubMed İndeksli Yayınlar Koleksiyonu İçin Listeleme
-
Correction: Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy
Karaçin, Cengiz; Öküzoğlu, Berna; Demirci, Ayşe; Keskinkılıç, Merve; Köse Baytemür, Naziyet; Yılmaz, Funda; Selvi, Oğuzhan; Erdem, Dilek; Avşar, Esin; Paksoy, Nail; Demir, Necla; Sezgin Göksu, Sema; Türker, Sema; Bayram, Ertuğrul; Çelebi, Abdüssamet; Yılmaz, Hatice; Kuzu, Ömer Faruk; Kahraman, Seda; Gökmen, İvo; Sakin, Abdullah; Alkan, Ali; Nayır, Erdinç; Uğraklı, Muzafer; Acar, Ömer; Ertürk, İsmail; Demir, Hacer; Aslan, Ferit; Sönmez, Özlem; Korkmaz, Taner; Celayir, Özde Melisa; Karadağ, İbrahim; Kayıkçıoğlu, Erkan; Şakalar, Teoman; Öktem, İlker Nihat; Eren, Tülay; Erül, Enes; Eylemer Mocan, Eda; Kalkan, Ziya; Yıldırım, Nilgün; Ergün, Yakup; Akagündüz, Baran; Karakaya, Serdar; Kut, Engin; Teker, Fatih; Çakan Demirel, Burçin; Karaboyun, Kubilay; Almuradova, Elvina; Ünal, Olçun Ümit; Oyman, Abdülkerim; Işık, Deniz; Okutur, Kerem; Öztosun, Buğra; Belen Gülbağcı, Burcu; Kalender, Mehmet Emin; Şahin, Elif; Seyyar, Mustafa; Özdemir, Özlem; Selçukbiricik, Fatih; Kanıtez, Metin; Dede, İsa; Gümüş, Mahmut; Gökmen, Erhan; Yaren, Arzu; Menekşe, Serkan; Ebinç, Senar; Aksoy, Sercan; İnanç İmamoğlu, Gökşen; Altınnbaş, Mustafa; Çetin, Bülent; Oyan Uluç, Başak; Er, Özlem; Karadurmuş, Nuri; Erdoğan, Atike Pınar; Artaç, Mehmet; Tanrıverdi, Özgür; Çiçin, İrfan; Şendur, Mehmet Ali Nahit; Oktay, Esin; Bayoğlu, İbrahim Vedat; Paydaş, Semra; Aydıner, Adnan; Kıvrak Salim, Derya; Geredeli, Çağlayan; Yavuzşen, Tuğba; Doğan, Mutlu; Hacıbekiroğlu, İlhan (BioMed Central, 2023)Background There is no standard treatment recommended at category 1 level in international guidelines for subsequent therapy after cyclin-dependent kinase 4/6 inhibitor (CDK4/6) based therapy. We aimed to evaluate which ... -
The effectiveness and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early-stage human epidermal growth factor receptor 2-positive breast cancer: Turkish Oncology Group study
Özdemir, Özlem; Zengel, Baha; Yıldız, Yaşar; Oyan Uluç, Başak; Çabuk, Devrim; Özden, Ercan; Kıvrak Salim, Derya; Paydaş, Semra; Demir, Atakan; Diker, Ömer; Pilancı, Kezban Nur; Uysal Sönmez, Özlem; Vatansever, Sezai; Doğan, İzzet; Gülmez, Ahmet; Çakar, Burcu; Gürsoy, Pınar; Yıldırım, Mahmut Emre; Ayhan, Murat; Karadurmuş, Nuri; Aykan, Musa Barış; Çevik, Gökçen Tuğba; Şakalar, Teoman; Hacıbekiroğlu, İlhan; Belen Gülbağcı, Burcu; Dinçer, Murat; Bayır Garbioğlu, Duygu; Kemal, Yasemin; Nayır, Erdinç; Taşkaynatan, Halil; Yılmaz, Mesut; Avcı, Okan; Sarı, Murat; Çoban, Ezgi; Atcı, Muhammed Mustafa; Aktürk Esen, Selin; Akın Telli, Tuğba; Karataş, Fatih; İnal, Ali; Demir, Hacer; Önal Kalkan, Nurhan; Yılmaz, Cengiz; Taşlı, Funda; Alacacıoğlu, Ahmet (Lippincott, Williams & Wilkins, 07.06.2022)In our study, we aimed to evaluate the pathological response rates and side effect profile of adding pertuzumab to the treatment of HER2+ locally advanced, inflammatory, or early-stage breast cancer. This study was conducted ... -
Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy
Karaçin, Cengiz; Öksüzoğlu, Berna; Demirci, Ayşe; Keskinkılıç, Merve; Köse Baytemür, Naziyet; Yılmaz, Funda; Selvi, Oğuzhan; Erdem, Dilek; Avşar, Esin; Paksoy, Nail; Demir, Necla; Sezgin Göksu, Sema; Türker, Sema; Bayram, Ertuğrul; Çelebi, Abdüssamet; Yılmaz, Hatice; Kuzu, Ömer Faruk; Kahraman, Seda; Gökmen, İvo; Sakin, Abdullah; Alkan, Ali; Nayır, Erdinç; Uğraklı, Muzaffer; Acar, Ömer; Ertürk, İsmail; Demir, Hacer; Aslan, Ferit; Sönmez, Özlem; Korkmaz, Taner; Celayir, Özde Melisa; Karadağ, İbrahim; Kayıkçıoğlu, Erkan; Şakalar, Teoman; Öktem, İlker Nihat; Eren, Tülay; Erül, Enes; Eylemer Mocan, Eda; Kalkan, Ziya; Yıldırım, Nilgün; Ergün, Yakup; Akagündüz, Baran; Karakaya, Serdar; Kut, Engin; Teker, Fatih; Çakan Demirel, Burçin; Karaboyun, Kubilay; Almuradova, Elvina; Ünal, Olçun Ümit; Oyman, Abdülkerim; Işık, Deniz; Okutur, Kerem; Öztosun, Buğra; Belen Gülbağcı, Burcu; Kalender, Mehmet Emin; Şahin, Elif; Seyyar, Mustafa; Özdemir, Özlem; Selçukbiricik, Fatih; Kanıtez, Metin; Dede, İsa; Gümüş, Mahmut; Gökmen, Erhan; Yaren, Arzu; Menekşe, Serkan; Ebinç, Senar; Aksoy, Sercan; İnanç İmamoğlu, Gökşen; Altınbaş, Mustafa; Çetin, Bülent; Oyan Uluç, Başak; Er, Özlem; Karadurmuş, Nuri; Erdoğan, Atike Pınar; Artaç, Mehmet; Tanrıverdi, Özgür; Çiçin, İrfan; Şendur, Mehmet Ali Nahit; Oktay, Esin; Bayoğlu, İbrahim Vedat; Paydaş, Semra; Aydıner, Adnan; Kıvrak Salim, Derya; Geredeli, Çağlayan; Yavuzşen, Tuğba; Doğan, Mutlu; Hacıbekiroğlu, İlhan (BioMed Central, 2023)Background: There is no standard treatment recommended at category 1 level in international guidelines for subsequent therapy after cyclin-dependent kinase 4/6 inhibitor (CDK4/6) based therapy. We aimed to evaluate which ... -
Evaluating the effect of tumor size and sidedness on prognosis in stage 2 colon cancer: a retrospective population study
Demir, Hacer; Çağlayan, D; Kaman, O; İnanç, M; Urvay, Semiha; Beypınar, İsmail; Demirci, A; Davarcı, Sena Ece; Araz, M; Baykara, Meltem; Artaç, M; Yıldız, F (Verduci, 2022)OBJECTIVE: In this study, we aimed to evaluate the effect of tumor size and tumor sidedness on prognosis in patients with stage 2 colon cancer. PATIENTS AND METHODS: Data of 501 patients diagnosed with stage 2 colon cancer ... -
A New Prognostic Index in Young Breast Cancer Patients
Demir, Hacer; Demirci, Ayşe; Karagöz Eren, Saliha; Beypınar, İsmail; Davarcı, Sena Ece; Baykara, Meltem (College of Physicians and Surgeons Pakistan, 2022)Objective:To evaluate the prognostic role of pan immune-inflammation value (PIV) in young breast cancer patients. Study Design: Descriptive study. Place and Duration of Study: Department of Medical Oncology, Afyon ... -
Prognostic role of pre-operative serum ferritin level in stage 2 colon cancer
Demir, Hacer; Beypınar, İsmail; Urvay, Semiha; Davarcı, Sena Ece; Baykara, Meltem (Verduci, 2021)OBJECTIVE: In this study, we aimed to evaluate the prognostic value of preoperative serum ferritin level in patients with stage 2 colon cancer who underwent curative surgery. PATIENTS AND METHODS: The data of 120 patients ... -
The Real-Life Data of BRAF Mutation on the Treatment of Colorectal Cancer: a TOG Study
Beypınar, İsmail; Demir, Hacer; Sakin, Abdullah; Yapar Taşköylü, Burcu; Sakalar, Teoman; Ergün, Yakup; Korkmaz, Mustafa; Ateş, Öztürk; Eren, Tülay; Turhal, Serdar; Artaç, Mehmet (Springer, 2021)Purpose Colorectal cancer is the third leading diagnosis accounting for nearly 10% of all new cancers worldwide. The distinct features among BRAF mutant colorectal cancers make these tumor groups hard to treat for oncologists. ... -
Survival of patients with metastatic rectum cancer who underwent metastasectomy following conversion chemotherapy sans pelvic radiotherapy: a Turkish oncology group study
Almuradova, Elvina; Yalcin, Suayib; Arıkan, Rukiye; Ayhan, Murat; Demir, Hacer; Çevik, Gökçen Tuğba; Karaca, Mustafa; Petekkaya, İbrahim; Karabulut, Bülent (CA : Cureus, 2023)Background: The management of early rectal cancer is different from that of colon cancer in terms of radiotherapy (RT) requirements or neoadjuvant treatment. It is not clear how the course of rectal cancer differs from ... -
Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer
Kahraman, Seda; Erul, Enes; Seyyar, Mustafa; Gümüşay, Özge; Bayram, Ertuğrul; Çakan Demirel, Burçin; Acar, Ömer; Aksoy, Sercan; Kose Baytemur, Naziyet; Şahin, Elif; Çabuk, Devrim; Basaran, Gül; Paydas, Semra; Yaren, Arzu; Güven, Deniz Can; Erdoğan, Atike Pınar; Demirci, Umut; Yaşar, Alper; Bayoğlu, İbrahim Vedat; Hizal, Mutlu; Gülbagci, Burcu; Paksoy, Nail; Davarci, Sena Ece; Yilmaz, Funda; Dogan, Özlem; Oyuncu Orhan, Sibel; Kayikcioglu, Erkan; Aytac, Ali; Keskinkilic, Merve; Eylemer Mocan, Eda; Unal, Olcun Umit; Aydin, Esra; Yucel, Hakan; Isik, Deniz; Eren, Onder; Oyan Uluc, Başak; Özcelik, Melike; Hacibekiroğlu, İlhan; Aydiner, Adnan; Demir, Hacer; Oksuzoğlu, Berna; Cilbir, Ebru; Cubukcu, Erdem; Cetin, Bulent; Oktay, Esin; Erol, Cihan; Okutur, Sadi Kerem; Yildirim, Nilgun; Alkan, Ali; Selcukbiricik, Fatih; Aksoy, Asude; Karakas, Yusuf; Ozkanli, Gulhan; Bozkurt Duman, Berna; Aydın, Dinçer; Dulgar, Özgecan; Er, Muhammed Muhiddin; Teker, Fatih; Yavuzsen, Tugba; Aykan, Musa Barış; İnal, Ali; Iriağac, Yakup; Onal Kalkan, Nurhan; Keser, Murat; Sakalar, Teoman; Menekse, Serkan; Kut, Engin; Bilgin, Burak; Karaoglanoglu, Muge; Sunar, Veli; Ozdemir, Özlem; Turhal, Nazim Serdar; Karadurmuş, Nuri; Yalçın, Bulent; Sendur, Mehmet Ali Nahit (Future Medicine Ltd., 2023)Background: Ribociclib, palbociclib and abemaciclib are currently approved CDK4/6 inhibitors along with aromatase inhibitors as the first-line standard-of-care for patients with hormone receptor-positive, HER2-negative ...